New vaccine against Shingles

Varicella zoster virus (VZV) causes chickenpox in children, teens and young adults and herpes zoster (shingles) in some patients (Ministry of Health, 2014). According to sero-epidemiological reports from hospitals, Sri Lanka demonstrate strong evidence of high level of susceptibility of VZV in the adult population. In 2003, 1.749 patients were reported at the government hospitals of which 15 reported fatal as indicated by Indoor Morbidity and Mortality Report (IMMR). In 2007, the Epidemiology unit reported approximately 3,435 cases which increased by 59.5% in
2008 reaching 5,493 patients with VZV infection (Agampodi et al., 2010).

A new vaccine, Shingrix, against Shingles has been developed by GlaxoSmithKline which has proven 90% effective in patients 50 years and older according to clinical trials carried out.